The Schall Law Firm Investigates Voyager Therapeutics, Inc. for Potential Securities Law Violations
Los Angeles, CA – March 2, 2025
The Schall Law Firm, a leading national securities firm, announces that it is investigating potential securities class action lawsuits on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ:VYGR) for possible violations of the federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Background on Voyager Therapeutics, Inc.
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing and commercializing innovative therapies for rare and severe neurological and neurodegenerative diseases. The Company’s proprietary AAV-based gene therapy platform is designed to address conditions such as Parkinson’s disease, Huntington’s disease, and other neurodegenerative disorders.
The Allegations
The Schall Law Firm’s investigation into Voyager is based on allegations that the Company issued false and misleading statements to the public. Specifically, the firm alleges that Voyager failed to disclose material information regarding the progress and safety of its clinical trials, as well as potential regulatory issues.
Impact on Investors
As a result of this investigation, investors who purchased or held Voyager securities between certain dates may have legal claims. The investigation is ongoing, and the Schall Law Firm encourages investors interested in learning more to contact the firm.
Implications for the World
The potential securities law violations at Voyager Therapeutics, if proven, could have far-reaching implications for the biotech industry as a whole. Investors rely on accurate and timely information when making investment decisions, and false or misleading statements can significantly impact market confidence and trust. It is crucial that companies maintain transparency and honesty in their communications with the public, particularly in the highly regulated and complex world of biotechnology.
Conclusion
The Schall Law Firm’s investigation into Voyager Therapeutics is an important reminder of the importance of transparency and honesty in the biotech industry. As the Company continues to develop innovative therapies for rare and severe neurological and neurodegenerative diseases, it is essential that it maintains the trust of its investors by providing accurate and timely information. The Schall Law Firm will continue to investigate the matter and keep the public informed of any developments.
- The Schall Law Firm is investigating potential securities class action lawsuits against Voyager Therapeutics, Inc.
- The investigation focuses on allegations that the Company issued false and misleading statements and failed to disclose material information.
- Investors who purchased or held Voyager securities between certain dates may have legal claims.
- The implications of these allegations could have far-reaching implications for the biotech industry as a whole.
- The Schall Law Firm will continue to investigate the matter and keep the public informed of any developments.
